Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.

Opis bibliograficzny
Główni autorzy:	Russell, N, Cull, G, Byrne, J, Stainer, C, Rebello, P, Hale, G, Waldmann, H, Haynes, A
Format:	Journal article
Wydane:	1999

Podobne zapisy

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
od: Cull, G, i wsp.
Wydane: (2000)

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
od: Cull, G, i wsp.
Wydane: (1999)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1988)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
od: Fibbe, W, i wsp.
Wydane: (1993)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
od: Chakrabarti, S, i wsp.
Wydane: (2004)

Availability of Campath-1 antibodies for bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1994)

Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation.
od: Mackinnon, S, i wsp.
Wydane: (1999)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
od: Potter, M, i wsp.
Wydane: (2000)

CAMPATH-1 antibodies in stem-cell transplantation.
od: Hale, G, i wsp.
Wydane: (2001)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
od: Rebello, P, i wsp.
Wydane: (1999)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
od: Waldmann, H, i wsp.
Wydane: (1987)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
od: Waldmann, H, i wsp.
Wydane: (1985)

ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES
od: Naparstek, E, i wsp.
Wydane: (1993)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
od: Friend, P, i wsp.
Wydane: (1988)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
od: Waldmann, H, i wsp.
Wydane: (1985)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
od: Erden Atilla, i wsp.
Wydane: (2017-02-01)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
od: Clatworthy, MR, i wsp.
Wydane: (2009)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
od: Hale, G, i wsp.
Wydane: (1998)

The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
od: Byrne, J, i wsp.
Wydane: (2000)

Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas
od: Gu Zhenyang, i wsp.
Wydane: (2021-03-01)

CAMPATH: from concept to clinic.
od: Waldmann, H, i wsp.
Wydane: (2005)

Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine
od: Andrew C. Harris, i wsp.
Wydane: (2018-06-01)

Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.
od: Chakrabarti, S, i wsp.
Wydane: (2003)

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
od: Heit, W, i wsp.
Wydane: (1986)

Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect
od: Enrico Maffini, i wsp.
Wydane: (2018-06-01)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
od: Hale, G, i wsp.
Wydane: (1986)

Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression.
od: Leong, L, i wsp.
Wydane: (1992)

RESULTS OF T-CELL DEPLETION WITH CAMPATH-1 IN BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL)
od: Apperley, J, i wsp.
Wydane: (1985)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
od: Watson, C, i wsp.
Wydane: (2004)

Specificity of monoclonal antibody Campath-1.
od: Hale, G, i wsp.
Wydane: (1988)

Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1985)

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial.
od: Friend, P, i wsp.
Wydane: (1989)

Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1.
od: Slavin, S, i wsp.
Wydane: (1985)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
od: Hale, G, i wsp.
Wydane: (1994)

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia
od: Ron Ram, i wsp.
Wydane: (2011-08-01)

T-cell depletion of bone marrow grafts with Campath 1 ex vivo prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation
od: Novitzky, N, i wsp.
Wydane: (1997)

Ex vivo T-cell depletion of bone marrow grafts with campath 1 prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation.
od: Novitzky, N, i wsp.
Wydane: (1997)

CAMPATH-1H for the treatment of acute rejection in kidney transplant recipients: 10 year follow-up
od: Clatworthy, MR, i wsp.
Wydane: (2007)

In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
od: Willemze, R, i wsp.
Wydane: (1992)